Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 1.00 |
| ▸ | CDK7 | P50613 | 10/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138529 | 0.91 | CHEK1 (0.83) | CHEK1CDK7SCN2ASCN10A | |
| SCHEMBL4292050 | 0.89 | CHEK1 (0.80) | CHEK1CDK7 | |
| SCHEMBL4294935 | 0.89 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL4297957 | 0.88 | CHEK1 (0.78) | CHEK1CDK7 | |
| SCHEMBL4296207 | 0.87 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL4294431 | 0.86 | CHEK1 (0.76) | CHEK1CDK7 | |
| SCHEMBL4294904 | 0.86 | CHEK1 (0.76) | CHEK1CDK7SCN2ASCN10A | |
| SCHEMBL13701623 | 0.85 | CHEK1 (0.74) | CHEK1CDK7SCN2ASCN10A | |
| SCHEMBL4287434 | 0.85 | CHEK1 (0.73) | CHEK1CDK7 | |
| SCHEMBL4292630 | 0.84 | CHEK1 (0.73) | CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | claimed |
| EP-1893607-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006135604-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | claimed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| EP-1893607-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135604-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CDK7 39/4885SCN2A 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.